

EMA/305826/2020

European Medicines Agency decision

P/0236/2020

of 12 June 2020

on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene (EMEA-001933-PIP01-16-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0236/2020

of 12 June 2020

on the acceptance of a modification of an agreed paediatric investigation plan for autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene (EMA-001933-PIP01-16-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0033/2017 issued on 31 January 2017,

Having regard to the application submitted by Orchard Therapeutics (Europe) on 24 January 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 30 April 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene, dispersion for injection, intraosseous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Orchard Therapeutics (Europe) Ltd, 108 Cannon Street, London EC4N 6EU, United Kingdom.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/76556/2020
Amsterdam, 30 April 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001933-PIP01-16-M01

Scope of the application

Active substance(s):

Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene

Condition(s):

Treatment of beta-thalassemia

Pharmaceutical form(s):

Dispersion for injection

Route(s) of administration:

Intraosseous use

Name/corporate name of the PIP applicant:

Orchard Therapeutics (Europe) Ltd

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Orchard Therapeutics (Europe) Ltd submitted to the European Medicines Agency on 24 January 2020 an application for modification of the agreed paediatric investigation plan with a waiver as set out in the European Medicines Agency's decision P/0033/2017 issued on 31 January 2017.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 2 March 2020.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.



Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of beta-thalassemia

The waiver applies to:

- the paediatric population from birth to less than 12 months;
- dispersion for injection, intraosseous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of beta-thalassemia

2.1.1. Indication(s) targeted by the PIP

Treatment of beta-thalassemia major and intermedia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Dispersion for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 1: Open-label, single-arm, single centre trial to evaluate the safety and efficacy of a single injection of haematopoietic stem cell gene therapy in patients with transfusion-dependent beta-thalassemia. Study 2: Open-label, single-arm, multi-centre trial to evaluate the safety and efficacy of a single injection of haematopoietic stem cell gene therapy in patients with transfusion-dependent beta-thalassemia.
Extrapolation, modelling and simulation studies	0	Not applicable.

Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2022
Deferral for one or more measures contained in the paediatric investigation plan:	No